Please assess the completion status of the following clinical trial:

Trial Title: HM242-Gel vs Comparator

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females of at least 18 years at the time of enrolment~2. The legal capacity and ability to understand the nature, risks, significance and scope of the clinical trial and to determine his or her will accordingly~3. Signed form of consent, including the understanding of and willingness by the patient to participate in the clinical study and ability to comply with study procedures and study visit schedule~4. Patients must be willing to have all dressing changes performed by the wound specialist, with no treatments at home~5. Presence of at least one venous ulcer of the lower leg extending through the full thickness of the skin but not down to muscle, tendon or bone~6. Size of study ulcer ≥ 2cm² and ≤ 100cm² measured using the tracing method.~7. Presence of venous leg ulcer for at least 6 weeks, but not longer than 12 months~8. Ankle Brachial Pressure Index (ABI) \> 0.75~9. In the case of a female patient of childbearing potential, willingness to use highly effective methods of contraception (failure rate of \< 1% when used consistently and correctly);acceptable contraceptive measures in this trial are: combined pill and progestin-only pill, contraceptive patch, ring or injection, Etonogestrel implant, intrauterine device (IUD) (copper and Levonogestrel), male sterilization (vasectomy), female sterilization (abdominal, laparoscopic, hysteroscopic), or sexual abstinence.~Exclusion Criteria:~1. Patients kept in an institution due to an official or court order~2. Patients dependent on the Sponsor, Investigator or Site~3. Patients suspected of having SARS-CoV-2 infection or COVID-19 disease~4. Study ulcer judged by the Investigator to be caused by a medical condition other than venous insufficiency~5. Study ulcer with signs and symptoms of infection, or under suspicion of cancer~6. Study ulcer under treatment with topical antimicrobials within past two weeks or systemic antimicrobial treatment within past two weeks~7. In the case of heavily exuding ulcers, if in the opinion of Investigator the patient is not suitable for treatment with gel~8. More than two venous leg ulcers or more than two chronic wounds~9. Dementia stage greater than 3 according to Reisberg~10. Known allergies against wound dressings used in the study~11. Known chronical skin diseases, dermatoses, or known allergies or other conditions which might trigger dermatitis~12. Acute cases of substance use disorders (ICD-10 F1x.1 or F1x.2)~13. Buerger's disease~14. Participation in Medical Device trials less than 4 weeks ago or participation in Drug trials less than six months ago~15. Terminally ill patients~16. Patients with poorly managed diabetes mellitus: absence of a glycated hemoglobin test within the last 3 months or a result of HbA1c ≥ 8% not older than 3 months, or a major diabetes-related incident within the past 4 weeks~17. Ulcers of diabetic origin~18. Patients under treatment with systemic corticosteroids, immunosuppressant, cytotoxic chemotherapy, or radiotherapy~19. Presence of one or more medical conditions (other than venous insufficiency and diabetes) as determined by medical history, which:~    * Is known to interfere with the wound healing process (e.g. arteriopathy, vasculitis, rheumatoid arthritis, systemic lupus erythematosus, other auto-immune diseases, cancer, immunodeficiency, severe lymphedema of the leg, thrombophilia)~   * In the opinion of the Investigator, would make the patient an inappropriate candidate for this venous ulcer healing study (e.g. malnutrition, hygiene, obesity)~20. Pregnant or lactating patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HM242-Gel (Type: EXPERIMENTAL): None
- Intrasite Gel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).